Patent · US Active

Use of ADIPOQ gene expression level for classification of a subject in risk groups in the prognosis or diagnosis of type II diabetes mellitus

US12203137B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

LIPOZYT MARKER UG · DE

Inventors

Uwe Jensen · Osnabrück, DE
Wolfgang Hierneis · Hamburg, DE
Markus KLEMKE · Bremen, DE
Helge Wilhelm THIES · Bremen, DE

Key dates

Filing date	Nov 19, 2018
Grant date	Jan 21, 2025
Priority date	—
Expiry date	Jul 7, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention is directed to using of the relative value of the gene expression level of the gene for ADIPOQ and/or of a gene, the expression of which has linear statistical correlation with that of the ADIPOQ gene, in the prognosis or the diagnosis of a type II diabetes mellitus disease in a test subject. Also disclosed is a method for prognosing and/or diagnosing a type II diabetes mellitus disease for classification of a subject into risk groups, wherein the gene expression level of the ADIPOQ gene and/or of a gene, the expression of which has linear statistical correlation with that of the ADIPOQ gene, is determined and the subject is subsequently classified into risk groups, taking said gene expression level into account.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.